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The Opioid Crisis Examined 
Abstract  
The Opioid Crisis is a national crisis affecting public, social, and economic healthcare.  Nearly 
50,000 deaths were caused by opioid overdoses in 2017. Current treatments of opioid addictions include 
the use of methadone and buprenorphine. These medications have been known to reduce opioid 
dependency, lower tolerances, increase the opioid overdose threshold, and lower overdose mortality. An 
analysis was conducted on prominent research studies investigating the effectiveness, safety, side effects, 
and influence of Methadone and Buprenorphine. The meta-analysis confirmed that both drugs are 
effective opioid agonists that contribute to decreased opioid dependence and increased opioid abstinence. 
Due to a series of factors including, overdose risk, patient satisfaction, efficiency, ease of use, and 
availability, buprenorphine is more effective than methadone. 
Introduction 
The Opioid Crisis is a national crisis affecting public, social, and economic healthcare.  Based on 
the CDC statistics, Opioids caused 47,600 overdose deaths in 2017. Nearly 70% of all drug overdoses are 
due to Opioids. Approximately 30% of patients that were prescribed opioids misuse them (CDC, 2018).  
Research has revealed that approximately 80 percent of heroin users initially abused prescribed opioids 
 (Muhuri, 2013).  Based on the National Institute on Drug abuse, hydrocodone (Vicodin®), oxycodone 
(OxyContin®, Percocet®), oxymorphone (Opana®) morphine, codeine and fentanyl are the most 
commonly prescribed opioids. There are two main types of opioids, synthetic and natural. Natural opioids 
are derived from the plant Papaver somniferum, also known as the opium poppy plant. The opium poppy 
plant can be processed in a series of mechanical and chemical steps to produce morphine and codeine. 
Synthetic opioids are lab made and include methadone and fentanyl. Other opioids are classified as semi -
synthetic, such as Oxycodone (Arfken, 2017). 
Pathophysiology of opioid receptors 
Opioids function in the body by activating nerve cell receptors that belong to a class of proteins 
called G protein-coupled receptors (GPCR).  There are three main GPCR’s called the Mu, Delta, and 
Kappa receptors that can be stimulated by opioid peptides (Scherrer, 2006). The Mu receptor has been 
discovered to play a substantial role in stimulation and addictive behaviors. The European College of 
Neuropsychopharmacology found that the lack of Mu receptors or the inhibition of the Mu receptors 
eliminated the analgesic effects of opioids, specifically morphine. Inhibited Mu receptors also led to a 
decrease in physical dependence to opioids. Opioid receptors are located in descending pain modulating 
pathways. G protein-coupled receptors activated in the midbrain; limbic, cortical structures inhibit 
neurons that transmit pain transmission (Al-Hasani, 2011). 
Opioid side effects fall into the subdivision of peripheral effects and central effects. Peripheral 
effects may include bronchospasm, hives, constipation, and urine retention. Central side effects include 
nausea, respiratory depression, sedation, hypotension, miosis, and cough suppression. Side effects from 
central and peripheral subdivisions affect the quality of life in patients with opioid dependency. (Ahlbeck 
K, 2011) Opioid tolerance inevitably leads to higher doses consumed to maintain the same analgesic 
effects. Increased tolerance exacerbates peripheral and central side effects. One of the greatest challenges 
of the opioid crisis is insufficient analgesia due to long term tolerance. The opioid crisis can be described 
 as a collection of events that occurred based on the time period they occurred in. There are three main 
waves.   
Waves of the opioid crisis 
1991 marked the first wave where opioid involved deaths sharply rose due to the increase and 
over-prescription of opioid medications for pain management. The over-prescription of opioids can be 
partially attributed to reassurance given to prescribers by pharmaceutical industries that opioid 
prescription addiction risks were low. Pharmaceutical companies also promoted the use of opioids in 
acute and non-cancer pain. In 1999, approximately 86% of patients that were prescribed opioids were 
originally prescribed opioids for non-cancer pain (Liu, 2019).  
The second wave of the opioid epidemic occurred around 2010 and was marked by an increase of 
heroin abuse related deaths. Heroin use increased in both sexes, social, and economic groups. This era 
also signified the first and early efforts to decrease opioid prescriptions.  The CDC stated that “Deaths due 
to heroin-related overdose increased by 286% from 2002 to 2013, and approximately 80% of heroin users 
admitted to misusing prescription opioids before turning to heroin (CDC).  
The third wave occurred in 2013 and was characterized by synthetic opioid related deaths 
specifically due fentanyl. The largest increase in synthetic opioid deaths was in 2016 with over 20,000 
deaths (Liu, 2019). As of August 27, 2019 , Purdue pharmaceuticals reached a settlement of 12 Billion 
dollars against 2000 opioid related lawsuits against Purdue's role in the exacerbation of the opioid crisis 
(Strickler, 2019). 
Opioid treatment  
Current treatments of opioid addictions include the use of methadone and buprenorphine. These 
medications have been established to reduce opioid dependency, lower tolerances, increase the opioid 
threshold to overdose, lower overdose mortality and increase the amount of time an addicted patient will 
 remain in opioid treatment. Methadone and buprenorphine lower the risks of transmitting infectious 
diseases such as HIV (National Institute on Drug Abuse. (2018, June).  
Methadone is a medication that is commonly used to treat patients suffering from opioid 
addiction. Methadone was discovered in 1938 and was approved for medicinal use in the United States in 
1947 and has been listed on the World Health Organization's List of Essential Medicines. Methadone 
treatment involves relieving cravings for opioids and blocking euphoria from opioids by binding to opioid 
receptors. Methadone is a full agonist. The receptors that Methadone binds to, are the same receptors that 
opioids such as heroin, morphine, and oxycontin bind to. When bound to those receptors in the brain, 
methadone does not release any euphoria and helps reduce opioid use urges.  Methadone treatment may 
be used as a maintenance therapy for long term opioid management or as a detoxification treatment that is 
short term and oriented at managing opioid withdrawal symptoms. The duration a patient may be on a 
methadone treatment plan varies widely. Since opioid addiction and dependency is considered a chronic 
disorder that may lead to relapse, methadone treatment may be lifelong for some patients.  
Buprenorphine was approved for medical use in the United States in 2002 by the U.S. Food and 
Drug Administration (FDA). Buprenorphine is commonly used to treat patients with an opioid addiction. 
Buprenorphine is a “partial opioid agonist” and attaches to opioid receptors to activate them. 
Buprenorphine does not activate the receptor as strong as an opioid narcotic would. Similar to methadone, 
buprenorphine reduces withdrawal symptoms in patients without producing opioid analgesic euphoria. 
Buprenorphine reduces cravings and is tolerated well by the body.  Prolonged buprenorphine treatment is 
associated with psychological or physical dependence. Once a patient has developed a tolerance toward 
buprenorphine and is stabilized on the medication then there are three treatment routes. These three routes 
include: “continual use, switching to buprenorphine/naloxone, or medically supervised withdrawal 
(Samhsa, 2016) ”.  
 Usually reported side effects of methadone treatment include chronic sweats, constipation, and 
sexual dysfunction. Buprenorphine common dosage route is sublingual administration and shows poor 
gastrointestinal absorption. Due to poor absorption, buprenorphine has a decreased risk of an overdose if 
accidentally ingested by non-tolerant individuals (Bonhomme).  Based on a study conducted by Al-
Gommer, fewer patients reported loss of erection, sexual fantasy and premature ejaculations on 
buprenorphine compared to methadone (Al-Gommer, 2007).  Buprenorphine abuse may lead to fatal 
respiratory depression. Buprenorphine shows difficulty in reversing respiratory depression due to 
antagonist effects (Megarbane, 2006). It was found that “0.8 mg of intravenous naloxone was ineffective 
in reversing buprenorphine-induced respiratory depression”. Naloxone had to be increased to 2-4 mg over 
a time of 30 minutes to fully reverse respiratory depression (Dorp, 2007).  Additional major differences 
collected between methadone and buprenorphine are summarized in Table 1 found in the appendix 
section (Bonhomme). 
Discussion 
A study conducted by Stone A.C (Methadone maintenance treatment among patients exposed to 
illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months) examined the effects of a 
6-month methadone treatment on opioid dependent patients. The main purpose of this study was to 
determine the effectiveness of methadone on attaining abstinence from fentanyl. A retrospective review of 
fentanyl addicted patients that were undergoing MMTP therapy was conducted. 
 Participants of Stones study were observed for time period of six months. Researchers focused 
on factors that included: patient retention in Methadone maintenance treatment therapy, fentanyl 
abstinence evidence, relapse, methadone dosage, and the amount of time to achieve opioid abstinence. 
Throughout the study, participants were randomly drug tested three times per month for a duration of six 
months. To prevent conflict of interest and bias, each drug test was administered and tested by an outside 
lab in a different state. There was no standard dosage of methadone. Each participant in the study had a 
 calculated dose of methadone that was specialized to their needs and was gradually increased throughout 
the length of the study. 
Participants used in the study included, 147 patient’s that tested positive for opioids at admission. 
The average age was 37 years old with a standard deviation of 11. 61% of the participants were male and 
81% of them were Caucasian. Within the 6-month study, 49 patients stopped treatment early (Stone, 
2018). 
Results of this study found that MMTP therapy was safe, effective, and facilitated abstinence 
from opioids. Within the remaining population, 71% of the participants reached abstinence within 6-
months (Stone, 2018).  Additionally, the study concluded that methadone treatment had raised tolerance 
levels in the patients so when a patient had relapsed, they did not overdose. Researchers suggested that if 
their tolerance was not raised by the methadone, a relapse could have killed them from the same dose 
taken at relapse. Methadone treatment did not have any significant effects on the rate of relapse. 
Methadone helped prevent overdose related mortality. The author mentioned that “Continued fentanyl use 
and relapse appears to be a problem in this cohort of methadone patients” and that sustained abstinence 
had occurred in the majority of patients. No deaths had occurred during the 6-month study. 
  This study was the first of its kind to investigate the results of MMT therapy on fentanyl addicted 
patients and was published by Elsevier, a global information analytic that specializes in health and 
science. Elsevier publishes quality research and clinical studies that have been peer reviewed by an 
editorial board. The study uses many relevant and credible sources to help support its claims. One of the 
referenced studies was “Arfken, C.L., Suchanek, J., Greenwald, M.K., 2017. Characterizing fentanyl use 
in methadone-maintained clients. J. Subst. Abuse Treat. 75, 17–21”. The study was approved by the 
Institutional Review Board at the Miriam Hospital in Providence, Rhode Island. 
The following study conducted by Bruera, researched and compared methadone and morphine’s 
side effects and effectiveness in patients with cancer pain. The name of the study is “Methadone versus 
 morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study”.  The conducted 
study was a double blind, randomized, parallel trial that was conducted in 7 palliative care facilities. 
  A total of 103 patients were included in the study. The patients in this study were randomly 
placed into two experimental groups. The first experimental group investigated the effects of methadone. 
Patients in the methadone section were administered 7.5mg of oral methadone every 12 hours and 5mg 
every 4 hours as needed for breakthrough pain (Bruera, 2004). The second group utilized in this study 
was the morphine group. Patients in the morphine section were administered 15mg of morphine twice 
daily and 5mg morphine as needed for breakthrough pain. The experiment lasted for 4 weeks and the 
patients were checked on daily for the first 8 days then were assessed on days 8, 15, 22, and 29. Pain was 
assessed using the Edmonton system for cancer pain. Factors including pain, nausea, constipation, and 
sedation were measured on a scale of 1-10. Pearson correlation coefficients were used to correlate 
outcome measures”. Nonparametric statistics were implemented to calculate the P values. In addition, the 
Wilcoxon rank sum test and Fisher’s exact test were utilized (Bruera, 2004). 
The two sections had comparable results for pain, sedation, nausea, confusion, and constipation. 
“Patients that received methadone had more opioid-related drop-outs (11 of 49; 22%) than those receiving 
morphine (three of 54; 6%; P =.019). The opioid escalation index at days 14 and 28 was similar between 
the two groups. More than three fourths of patients in each group reported a 20% or more reduction in 
pain intensity by day 8. The proportion of patients with a 20% or more improvement in pain at 4 weeks in 
the methadone group was 0.49 (95% CI, 0.34 to 0.64) and was similar in the morphine group (0.56; 95% 
CI, 0.41 to 0.70)” (Bruera, 2004). Opioid escalation was calculated using the formula in table 2 found in 
the appendix section.  Results concluded that twice daily, 15 mg/day total methadone did not produce 
better cancer pain relief compared to 30 mg/day sustained-release morphine (Bruera, 2004). Table 3 
displays the pain response from the patients in the appendix section.  
 Bruera’s study was published by the journal of Clinical oncology, an American society of clinical 
oncology journals. The journal of Clinical oncology specializes in publishing quality research articles. 
The majority of the articles published relate to patients with cancer and are peer reviewed. The author, 
Bruera E has published many other quality articles including, “Symptom distress in advanced cancer 
patients with anxiety and depression in the palliative care setting.” and “Prescribing patterns and 
purchasing costs of long-acting opioids over nine years at an academic oncology hospital.” This research 
also referenced 37 studies that relate to cancer analgesia.  
The following study, “Dose-response effects of methadone in the treatment of opioid 
dependence” was conducted in 1993 by Strain EC. 247 participants with an average age of 34 years old 
participated. 70% of the participants were male and 50% were African American. For a participant to be 
eligible for this study they had to be within 1850 years old, have a history of opioid dependent and have 
no chronic physical or mental illness.  
Intervention included methadone treatment of a steady dose of methadone for the first 5 weeks 
and then a various steady dose (50mg, 20mg, or 0mg) for the following 15 weeks. Participants were 
originally started on 25mg of methadone for the first week of the study and then were randomized into 
different dosage groups for the remainder of the study.  Methadone tapering was conducted in weeks 21-
26. Group and individual counseling was provided on a weekly basis. Opioid levels of all the patients in 
the study were monitored by urine testing.  
Results confirmed that methadone is an effective treatment plan for assisting opioid addicted 
patients achieve abstinence and recovery. The study measured results based on patient retention to 
treatment and their illicit drug use.  The 20th treatment week showed a 52% treatment retention rate for 
the 50mg group, 41.5% for the 20mg group, and 21% for the 0mg group. Only the 50mg group had the 
rate of illicit drug use decrease (56.4% for 50mg, 67.6% for the 20mg group, and 73.6% for the 0mg 
groups). The main results indicated that methadone treatment improves retention but is inadequate in 
 significantly suppressing illicit drug use. Major results of this study are presented in table 4 in the 
appendix section.  
Furthermore, a study conducted in 2008 by Gruber investigated the effects of methadone 
detoxification compared to methadone maintenance with minimal counseling and methadone maintenance 
standard counseling. The study investigated and compared three treatments to each other. Treatments 
investigated in this study included six months of methadone maintenance with standard or minimal 
counseling compared to a 21 day methadone detoxification.  The study conducted was a randomized, 
double-blind, prospective trial.  
Methadone detoxification programs are common for patients that have partial access to 
methadone maintenance treatment programs. Limitations to methadone maintenance treatment programs 
are due to a lack of insurance coverage, methadone prescribers, and distance. Patients used in the study 
originated from a public hospital’s 21 day methadone detoxification program. A statistician randomly 
sorted 111 patients into three treatment groups. Patients received a sealed envelope with the group they 
would be participating in. The staff were unaware of which group the patients were in. Urine drug tests 
and self reported tests were collected at 1, 6, and 8 month intervals.  
Results of this study concluded that compared to a 21 day detoxification treatment, a six month 
methadone maintenance program resulted in fewer opiate positive drug tests. In both six month 
maintenance groups, self reported alcohol and heroin use was lower. Standard vs minimal counseling did 
not result in statistically significant differences in outcomes. In months 1-6, participants in the 
detoxification group resulted in 78%-96% opioid positive drug test results. This group of patient’s also 
reported an average use of heroin of 15.5–18.4 days in each follow up. The six month methadone 
maintenance program showed a greater decrease of opioid positive drug tests (65%–85%). Self-reported 
heroin and alcohol also decreased to an average of  5.8–8.1 days in each month. The study concluded that 
six months of methadone maintenance reduced heroin and alcohol use as well as lowered opioid positive 
 drugs treats more effectively than 21-day methadone detoxification. Another study conducted in 2005 by 
Amato et al concluded similar results. The study found that Methadone detoxification is not an effective 
treatment for opioid dependence (Amato et al., 2005b). 
Results did not show significant differences between standard and minimal counseling over the 
six month periods. In contrast to these results, in 1993 McLellan et al found that in long term methadone 
maintenance programs standard counseling resulted in fewer opioid positive urine results when compared 
to minimal counseling (McLellan et al., 1993). 
An additional study conducted by sabzghabaee investigated the effects of both intranasal and 
intravenous administration of naloxone in overdosed patients. 
Overdosed Patients administered to Noor and Ali Asghar Hospital were immediately randomly placed 
into one of two treatment groups. The first group received naloxone administration through IV and the 
second group received intranasal administered naloxone. A total of 100 patients participated in this study. 
The ages of the participants ranged from 15-50. The study was approved by the Ethics Committee of 
Isfahan University and registered with clinicalTrials.gov. After Naloxone administration, blood pressure, 
heart rate, respiratory rate, and level of consciousness were measured. Researchers measured additional 
factors including: time to response, arterial blood oxygen saturation, agitation, and duration of hospital 
stay. The primary factor measured was consciousness measured by the Glasgow Coma Scale (GCS). 
Table 5 displays the level of consciousness before and after naloxone administration split by the 
intranasal and intravenous group.  
Patients who had been administered intranasal naloxone demonstrated significantly higher levels of 
consciousness than those in the intravenous group using both descriptive and GCS scales (p < 0.001). 
There was a significant difference in the heart rate between intranasal and intravenous groups (p = 0.003). 
However, blood pressure, respiratory rate and arterial O2 saturation were not significantly different 
 between the two groups after naloxone administration (p = 0.18, p = 0.17, p = 0.32). There was also no 
significant difference in the length of hospital stay between the two groups (p = 0.14). 
 This study was published by the journal, Archives of Medical Science (AMS). AMS publishes 
quality medical papers globally and all of them are peer reviewed by an international editorial board. The 
main authors in this study come from various high level medical backgrounds including, toxicology and 
anesthesiology. The study were randomized and conducted by the Department of Poisoning Emergencies 
at Noor and Ali Asghar Hospital in Iran. The author used many other prominent research articles to 
support his results and the author formed a sound and logical rationale for the study. 
The study conducted by Marteau D assessed the mortality rates of methadone and buprenorphine 
within the population of England and Wales. The researchers first determined the total quantities of 
methadone and buprenorphine dispensed in England and Wales from 2007 to 2012. Data was collected 
from the National Health Service in England, and the National Health Service in Wales. “Mortality data 
were drawn from the Office for National Statistics ‘Deaths Related to Drug Poisoning in England and 
Wales’” (Marteau, 2015).  The sample included 2,366 methadone-related deaths and 17,333,163 
methadone prescriptions as well as 52 buprenorphine related deaths and 2,602,374 buprenorphine 
prescriptions. Table 6 displays the total methadone and buprenorphine related death rate per 1000 issued 
prescriptions. Results concluded that buprenorphine was six times safer than methadone. Directly from 
the study, “Among the whole population of England and Wales, there were 0.137 methadone-related 
deaths per 1,000 prescriptions of methadone and 0.022 buprenorphine-related deaths per 1,000 
prescriptions of buprenorphine-based drugs for the substitution treatment of opioid dependence” 
Limitations  
The study Conducted by Stone, AC had elements of randomization and blindness although the study 
itself was not double blind. Patients were randomly selected for the study and had randomized drug tests. 
The author also stated that “The patient population at the MMTP that participated in this study may not be 
 representative of methadone patients in other regions”. The results and findings of this study were limited 
by the short length and the small population size of the study. The size originally was small at 113 
patients, but the number quickly shrank as participants withdrew from the study. At the end of the 4 
months, 47 patients withdrew from the study. The results were drawn from the results of only 66 patients. 
Methadone treatment varies based on location, the amount of tolerance a patient has, the type and the 
combination of drugs a patient has in their system. The researchers also acknowledged that the conversion 
of doses from methadone to morphine may have been off and the methadone dose was higher than it 
should have been. The higher than needed dose could have explained the toxicity in the methadone group. 
Overall the limitations were significant and could have influenced the results of the study. 
In the study comparing intranasal naloxone to intravenous naloxone, level of consciousness was 
measured using descriptive scales (lethargic, conscious, obtundation, stupor, and coma) and the Glasgow 
Coma Scale (GCS). There could have been some limitations or bias in the level of consciousness test. The 
main bias in the study was unknown patient history. Many of the participants were heavy drug abusers 
that had incomplete or nonexistent medical histories. Limitations are addressed by the author in the study. 
One of the limitations included the small and not necessarily “representative of all” population used in the 
study. Participants were not screened and randomly selected for the study. This leads us to the next 
observed limitation which is the substance that the patient had overdosed on. Some participants did not 
regain complete consciousness after being administered Naloxone, indicating that the drugs in the body 
were not opioids. The major source of bias that could have occurred is the researches not knowing what 
substance the patient had overdosed on.  
Marteau’s study was one of the first studies conducted regarding overdose mortality rates being 
compared between methadone and buprenorphine. Suggestions were made to have additional studies in 
different areas of the world to compare results. The major limitations of this study included unidentified 
differences in drug dependence between patients. Additionally, the number of buprenorphine 
prescriptions was calculated based on mean doses. 
 Conclusion 
Methadone and buprenorphine are both useful in helping patients struggling with opioid 
addiction.  Methadone has been one of the most prominent and oldest treatment options for opioid 
addiction. The availability of methadone is disadvantageous when compared to buprenorphine. 
Methadone is only prescribed and distributed in specialized clinics while buprenorphine prescriptions 
may be picked up and taken home by patients. Buprenorphine is also easier to be prescribed by physicians 
and allows more patients to be monitored by one physician. Buprenorphine is only a partial agonist while 
methadone is a full opioid agonist. Buprenorphine is generally safer to use than methadone partially due 
to its “ceiling effect”.  Because of the ceiling effect, buprenorphine’s effects do not increase after a certain 
point, even with increases in dosage. This helps reduce the risk of overdose and respiratory depression 
from occurring. Additionally, buprenorphine has shown a decrease of overdose risk due to its sublingual 
administration. Due to poor absorption, buprenorphine has a decreased risk of an overdose if accidentally 
ingested by non-tolerant individuals (Bonhomme).  Further confirmation of buprenorphine’s safety can be 
drawn from Marteau D study. “Among the whole population of England and Wales, there were 0.137 
methadone-related deaths per 1,000 prescriptions of methadone and 0.022 buprenorphine-related deaths 
per 1,000 prescriptions of buprenorphine-based drugs for the substitution treatment of opioid 
dependence”. A comparison of side effects indicated that buprenorphine causes less withdrawal 
symptoms when abruptly stopped compared to methadone (Schottenfeld RS, 1997). Fewer patients 
reported loss of erection, sexual fantasy and premature ejaculations on buprenorphine compared to 
methadone (Al-Gommer).  When facing an over-dose from any opioid, Sabzghabaee study concluded that 
intranasal naloxone is an effective and life saving medication that is easy to administer in emergency 
situations to reverse opioid overdose.  
 Both methadone and buprenorphine are effective drugs at helping patients manage opioid 
addiction. Due to a series of factors including, overdose risk, patient use, efficiency, and ease of use and 
availability, buprenorphine is more effective than methadone.  
                                                                         Appendix 
Table 1 
  
 
 
 
 
 
Table 2 
 
 Table 3 
 
 
Table 4 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 6 
 
 
 
 
 
 
 
 
Table 5 
 
   
Works cited  
1) 
Stone A.C., Carroll J.J., Rich J.D., Green T.C. (2018) Methadone maintenance treatment among patients exposed to  
illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months. Drug and Alcohol 
Dependence, 192 ,94-97. 
2) 
Sabzghabaee AM, Eizadi-Mood N, Yaraghi A, Zandifar S. (2014). Naloxone therapy in opioid overdose patients: 
intranasal or intravenous? A randomized clinical trial. Arch Med Sci.10(2):309–314. 
doi:10.5114/aoms.2014.42584 
3) 
Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, … Fisch MJ. (2004). Methadone versus 
morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. Journal of 
Clinical Oncology, 22(1), 185–192. 
4) 
 Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine       within   
the wider population of England and Wales. BMJ Open 2015;5:e007629. doi: 10.1136/bmjopen- 2015-
007629 
5) 
 Bruchas, Michael R., Ph.D. (2011/12/01/). Molecular Mechanisms of Opioid Receptor-dependent Signaling and 
Behavior. Anesthesiology: The Journal of the American Society of Anesthesiologists, 115, 1363-1381. 
6) 
 Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Laustriat D, Cao YQ, Basbaum AI, Dierich A, Vonesh JL, 
Gaveriaux-Ruff C, Kiefer BL. Knockin mice expressing fluorescent delta-opioid receptors uncover G 
protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci USA 2006;103(25):9691-6 
7) 
 Bonhomme, J., Shim, R. S., Gooden, R., Tyus, D., & Rust, G. (2012). Opioid addiction and abuse     in primary care 
practice: a comparison of methadone and buprenorphine as treatment options.   Journal of the National 
Medical Association, 104(7-8), 342–350.  doi:10.1016/s0027-9684(15)30175-9 
8) 
Strain EC, Stitzer ML, Liebson IA, et al. Dose-Response Effects of Methadone in the Treatment of Opioid 
Dependence. Ann Intern Med. 1993;119:23–27. doi: https://doi.org/10.7326/0003-4819-119-1-
199307010-00004 
 
 
 
 9) 
Strickler, L. (2019, August 28). Purdue Pharma offers $10-12 billion to settle opioid claims. Retrieved from 
https://www.nbcnews.com/news/us-news/purdue-pharma-offers-10-12-billion-settle-opioid-claims-
n1046526. 
10) 
Valerie A. Gruber, Kevin L. Delucchi, Anousheh Kielstein, Steven L. Batki, A randomized trial of 6-month 
methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification, 
Drug and Alcohol Dependence, Volume 94, Issues 1–3, 
11) 
McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. Management of 
opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain. 
2003;4:231–256. 
12) 
CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health 
and Human Services, CDC; 2018. https://wonder.cdc.gov. 
13) 
 Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use 
in the United States. CBHSQ Data Rev. August 2013. 
 
14) 
National Institute on Drug Abuse. (n.d.). How effective are medications to treat opioid use disorder? Retrieved from 
https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-
addiction/efficacy-medications-opioid-use-disorder. 
15) 
Arfken, C.L., Suchanek, J., Greenwald, M.K., 2017. Characterizing fentanyl use in methadone-maintained clients. J. 
Subst. Abuse Treat. 75, 17–21 
 
16) 
     Ahlbeck K. Opioids: a two-faced Janus. (2011). Current Medical Research & Opinion, 27(2), 439–448. https://doi-
org.ezproxylocal.library.nova.edu/10.1185/03007995.2010.545379 
17) 
Al-Gommer O, George S, Haque S, et al. Sexual dysfunctions in male opiate users: a comparative study of heroin, 
methadone, and buprenorphine. Addict Disord Treat. 2007;6(3):137. 
 
18) 
Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression?: Possible 
mechanisms and therapeutic consequences. Toxicol Rev. 2006;25(2):79–85. 
 19) 
Van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. 
Anesthesiology. 2006;105(1):51. 
20) 
 National Institute on Drug Abuse. (2018, June). How effective are medications to treat opioid use disorder? 
Retrieved from https://www.drugabuse.gov/publications/research-reports/medications-to-treat-
opioid-addiction/efficacy-medications-opioid-use-disorder. 
21) 
Liu, L. (2019, November 13). History of the Opioid Epidemic. Retrieved from 
https://www.poison.org/articles/opioid-epidemic-history-and-prescribing-patterns-182. 
 
 
